LPT 111111- A Single-Arm, Multicenter Phase II Study to Evaluate The Combination of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel or ABRAXANE) and Lapatinib (TYKERB) in Women With No More Than One Prior Treatment for ErbB2 Overexpressing Metastatic Breast Cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Jul 2017
At a glance
- Drugs Lapatinib (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Novartis
- 07 Mar 2017 Planned End Date changed from 1 Mar 2017 to 1 Dec 2017.
- 01 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Mar 2017.
- 01 Feb 2016 Planned End Date changed from 1 Dec 2015 to 1 Jun 2016 as reported byClinicalTrials.gov record.